Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174056 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT01174056: Completed Early Phase 1 study, sponsored by Washington University School of Medicine.
NCT01174056 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 39 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01174056, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this research study is to gain understanding of the basic responses of the lung to inflammation and specifically if a certain medication can reduce the inflammation alone or in combination with another. Inflammation is the way our bodies react to irritation or injury, and involves red, warm, and often painful swelling of the affected tissue. "Acute lung injury" involves inflammation that is not specific to one area of the lung and is caused by any one of several conditions: infection, trauma, breathing toxic substances, etc. When lung injury is severe, not enough oxygen can get into the body; this can lead to the need for mechanical support of breathing (mechanical ventilation), problems with brain, heart or other organ function, and in some cases, death.
Primary Outcome
Ki will be measured before and after endotoxin. Primary outcome measure is change in Ki (post- minus pre-endotoxin value) and absolute Ki after endotoxin.
Interventions
- DRUG Pioglitazone
- DRUG Zileuton
- DRUG Pioglitazone placebo
- DRUG Zileuton placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-03 |
| Phase | Early Phase 1 |
What the finished NCT01174056 record still lists
NCT01174056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 4 interventions - of which Pioglitazone is the first listed.
NCT01174056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01174056 about?
NCT01174056 is a clinical study titled "Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging". The purpose of this research study is to gain understanding of the basic responses of the lung to inflammation and specifically if a certain medication can reduce the inflammation alone or in combination with another. Inflammation is the way our bodies react to irritation or injury, and involves red...
What is the current status of trial NCT01174056?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2011-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01174056?
The interventions under investigation include: Pioglitazone (DRUG), Zileuton (DRUG), Pioglitazone placebo (DRUG), Zileuton placebo (DRUG).
Who is sponsoring clinical trial NCT01174056?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01174056's enrollment target sits among peer trials
39 689th of 2000 higher than 1,303 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia